Developer docs
API playgroundTry for free, no card

Search company profiles

Virbac

Full company profile

uuid00064iu

Namestring
Virbac
Legal namestring
VIRBAC
Websiteurl
virbac.com
Company typeenum
Public
Founded yearint
1968
Descriptiontext

Virbac is a French animal health pharmaceutical company founded in 1968 and headquartered in Carros, France, listed on Euronext Paris (EPA:VIRP). It develops, manufactures, and distributes veterinary medicines, vaccines, parasiticides, dermatology products, dental products, diagnostics, nutritional supplements, and specialty therapeutics for companion animals (cats, dogs) and food-producing animals (cattle, swine, aquaculture). The company holds the #1 veterinarian-recommended dental brand (C.E.T.) and operates flagship parasiticide franchises including Sentinel and Iverhart, alongside newer specialty assets such as URSOLYX (feline muscle health) and Felanorm/Thyronorm (feline hyperthyroidism). Manufacturing is conducted at facilities in France, the United States, Argentina, Japan, India, and Chile, supported by wholly-owned distribution subsidiaries in 100+ countries.

The business operates on a B2B go-to-market model selling through veterinary clinics, animal health distributors, and online retailers, with end users including veterinarians, farmers, breeders, and pet owners. Revenue is split roughly 60% companion animals and 40% food-producing animals, with FY2025 revenue of €1.465 billion (7.9% organic growth) and Q1 2026 revenue of €384 million (+7.7%). The product mix is dominated by one-time pharmaceutical sales rather than recurring subscriptions. Growth has been substantially augmented by an active M&A program, including the €280 million Sasaeah acquisition (Japan, 2024), £100 million Felanorm/Thyronorm acquisition (2025), and earlier $410 million Sentinel brands acquisition from Eli Lilly (2015), alongside licensing deals such as the MabGenesis monoclonal antibody agreement (2025).

The company is led by CEO Paul Martingell and CFO Habib Ramdani, with governance undergoing a 2026 regional reorganization into three major regions. Virbac's strategic positioning emphasizes species-specific innovation, global distribution scale, and post-acquisition portfolio integration rather than technology-platform differentiation.

Short descriptiontext

Virbac is a French-listed veterinary pharmaceutical company that develops, manufactures, and distributes medicines, vaccines, parasiticides, dental, dermatology, and nutrition products for companion animals and livestock across 100+ countries, selling primarily through veterinary clinics, distributors, and online retailers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersCarros, France
HQ citystring
Carros
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
veterinary pharmaceuticals, animal health products, veterinary vaccines, companion animal medicine, livestock pharmaceuticals
Industry4 codes
PRIMARYHLAMAEAL
Veterinary Vaccines (Biologics)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAEAK
Biologics & Immunotherapies (Non-vaccine)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAEAD
Parasiticides & Ectoparasite Control (Flea/Tick/Heartworm)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYAFAEANAK
Veterinary Pharmacy, Vaccine & Biologics Services
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Animal Food Manufacturing31111
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Veterinary Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Veterinary Pharmaceuticals and Medicines
TypeOne Time License
Description

Revenue generated from selling veterinary medicines, vaccines, parasiticides, antibiotics, and dermatology products to veterinarians and animal health distributors

ad-hoc-news.de
2Companion Animal Products
TypeOne Time License
Description

Products for cats and dogs including nutritional supplements, dental care, dermatology, parasiticides, representing approximately 60% of total sales

corporate.virbac.com
3Food-Producing Animal Products
TypeOne Time License
Description

Products for cattle, swine, aquaculture including vaccines, antibiotics, and health management solutions

corporate.virbac.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1C.E.T.
Description

Veterinary dental brand, #1 veterinarian-recommended dental brand

prnewswire.com
+3 more records
Core offering1 text field

Virbac develops, manufactures, and sells a comprehensive range of veterinary pharmaceuticals, vaccines, parasiticides, dermatology products, diagnostics, dental care solutions, and nutritional supplements for companion animals (cats and dogs) and food-producing animals (cattle, swine, aquaculture, poultry). The portfolio includes proprietary brands such as C.E.T.® dental products, Sentinel® and Iverhart® parasiticides, URSOLYX™ muscle health supplements, and Thyronorm/Felanorm for feline hyperthyroidism. Products are distributed globally in more than 100 countries through veterinary clinics, animal health distributors, and online retailers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • C.E.T. AQUADENT FR3SH Dental Solution received VOHC Seal of Acceptance for plaque and tartar control
+1 more record
Product overview1 text field

Virbac is a global animal health company offering a comprehensive and practical range of veterinary products and services covering the majority of animal species and diseases. The company's portfolio includes companion animal health solutions (dermatology, parasiticides, vaccines, diagnostics, nutritional products including C.E.T.® dental products, and antibiotics), farm animal health products (cattle, aquaculture/salmon, swine), and specialty pharmaceuticals. Key products include C.E.T. AQUADENT® FR3SH® Dental Solution, URSOLYX™ Soft Chews for Cats, Sentinel® and Iverhart® parasiticide brands, and feline hyperthyroidism treatments (Thyronorm, Felanorm). The company has expanded through acquisitions including Globion (India poultry vaccines), Sasaeah (Japan farm animal vaccines), Centrovet (Chile aquaculture), and licensing agreements for therapeutic antibodies. Virbac serves veterinarians, farmers and pet owners in more than 100 countries.

Product and service15 records
1C.E.T. AQUADENT FR3SH Dental Solution
CategoryCompanion animal dental product
Description

Veterinary dental solution for dogs that controls plaque and tartar; carries the VOHC Seal of Acceptance and is sold through veterinary clinics and leading online retailers.

2URSOLYX Soft Chews for Cats
CategoryCompanion animal nutritional supplement
Description

First muscle health supplement specifically formulated for cats to address muscle atrophy in aging, active or recuperating felines; key ingredient is ursolic acid; sold to veterinarians and through retail channels.

3Felanorm Oral Solution
CategoryCompanion animal pharmaceutical
Description

Leading drug for feline hyperthyroidism acquired by Virbac from Norbrook; expands Virbac's portfolio of treatments for senior cats.

4Thyronorm
CategoryCompanion animal pharmaceutical
Description

Liquid treatment for feline hyperthyroidism; distribution planned across UK, Australia, New Zealand and US markets; aids administration in cats.

5Sentinel Flavor Tabs
CategoryCompanion animal parasiticide
Description

Major parasiticide for dogs acquired by Virbac from Novartis Animal Health; generates approximately $90-100 million in revenues in the United States.

6Sentinel Spectrum
CategoryCompanion animal parasiticide
Description

Major parasiticide for dogs acquired by Virbac from Novartis Animal Health; generates approximately $90-100 million in revenues in the United States.

7Iverhart Plus
CategoryCompanion animal internal parasiticide
Description

Internal parasiticide for dogs; part of Virbac's canine parasiticide portfolio in the United States.

8Iverhart Max
CategoryCompanion animal internal parasiticide
Description

Internal parasiticide for dogs combining three active ingredients to provide wider protection including heartworm and tapeworm; marketed through veterinary channels in the United States.

9Milpro
CategoryCompanion animal internal parasiticide
Description

Internal parasiticide for companion animals launched in France and Northern Europe as part of Virbac's parasiticide range.

10Effitix
CategoryCompanion animal parasiticide
Description

Parasiticide product for companion animals launched in Europe; part of Virbac's external parasiticide portfolio.

11Centrovet Aquaculture Products
CategoryAquaculture pharmaceutical
Description

Aquaculture pharmaceutical products from Centrovet (Chile), a wholly-owned Virbac subsidiary, providing protection and treatment solutions for salmon and other aquaculture breeding operations.

12Globion Poultry Vaccines
CategoryPoultry vaccine
Description

Poultry vaccines from Globion India (now wholly-owned Virbac subsidiary), bolstering Virbac's position in the avian vaccines segment in India.

13Sasaeah Animal Health Products
CategoryFarm animal pharmaceutical
Description

Farm animal vaccines and pharmaceutical products from Sasaeah (Japan), a wholly-owned Virbac subsidiary with leadership in the Japanese cattle vaccine market and a broad pharmaceutical portfolio for major species.

14C.E.T. Dental Products
CategoryCompanion animal dental product line
Description

The number one veterinarian-recommended dental brand for pets, including dental solutions and hygiene products covering plaque and tartar control.

15iVet Specialty Petfood
CategoryCompanion animal petfood
Description

Specialty petfood from iVet LLC (USA), a wholly-owned Virbac subsidiary bringing distribution, logistics and e-commerce expertise for petfood in the United States.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-06-18
Description

Petlove, Brazil's largest pet ecosystem, partnered with Virbac as one of the major pharmaceutical firms for its PetVet medication benefits program offering up to 40% discounts on approximately 140 veterinary medications, targeting Brazil's 160 million pets

Strategic tierMinorTypeOthersAnnounced on2026-04-10
Description

Sébastien Huron, former CEO of Virbac (2017-2024), appointed as Deputy CEO of Ceva Animal Health as part of governance evolution

3HABRI (Human Animal Bond Research Institute)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-17
Description

Partnership to promote research and education on the human-animal bond and its health benefits, translating scientific research into practical insights for veterinary professionals and pet owners

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-16
Description

Licensing agreement for therapeutic antibodies for canine diseases, expanding pipeline in monoclonal antibody therapeutics

5MACSO
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-10-18
Description

Agreement for swine health products, announced October 2024

corporate.virbac.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-12-08
Description

Collaboration with Pharmgate for FDA approval of tulathromycin injectable in the United States

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-29
Description

Collaborative agreement for development of animal health vaccine(s), announced September 2021

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Elanco is a global animal health company focused on companion animal and livestock pharmaceuticals, vaccines, and parasiticides. Its companion animal focus and product mix closely resemble Virbac's strategic priorities.

TypeDirect peer
Description

Norbrook is a Northern Ireland-based veterinary pharmaceuticals company specializing in parasiticides, anti-infectives, and specialty therapeutics. Virbac acquired Thyronorm/Felanorm from Norbrook in 2025, evidencing direct portfolio overlap and competitive proximity.

TypeDirect peer
Description

Vetoquinol is a French-headquartered global animal health company specializing in veterinary pharmaceuticals and supplements for companion and production animals. Its portfolio and geographic mix closely parallel Virbac's, making it a strong mid-cap peer.

TypeDirect peer
Description

MSD Animal Health is a leading global animal health division offering pharmaceuticals, vaccines, and parasiticides; it acquired Sentinel US rights from Virbac in 2020 and competes across Virbac's full portfolio breadth.

TypeDirect peer
Description

Phibro is a global animal health and nutrition company offering vaccines, parasiticides, and nutritional specialties for livestock and poultry, with strong overlap to Virbac's food-producing animal segment.

TypeDirect peer
Description

Dechra is a UK-based specialty veterinary pharmaceuticals company focused on companion animal endocrinology, dermatology, and critical care, overlapping with Virbac's specialty therapeutics and parasiticide franchises.

TypeDirect peer
Description

Zoetis is the world's largest pure-play animal health company, offering pharmaceuticals, vaccines, diagnostics, and parasiticides across companion and livestock animals. It is the closest direct competitor to Virbac across virtually every product category and geography.

TypeDirect peer
Description

Ceva is a France-based global animal health company providing vaccines, pharmaceuticals, and companion animal products. As a fellow French-headquartered peer of similar size and scope, it is a closely comparable direct competitor, especially in Europe and emerging markets.

TypeBroad incumbent
Description

IDEXX is a leading veterinary diagnostics company offering in-clinic lab equipment and tests; while diagnostics is only a portion of Virbac's portfolio, IDEXX is a benchmark for veterinary channel economics and product premium pricing.

10Boehringer Ingelheim Animal Health
TypeDirect peer
Description

Boehringer's animal health division offers a broad portfolio of veterinary vaccines, parasiticides, and therapeutics for companion and food-producing animals, directly overlapping with Virbac's core franchises. It is one of the top global animal health players.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A8 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Virbac

Veterinary Pharmaceuticalsvirbac.com

Virbac is a French-listed veterinary pharmaceutical company that develops, manufactures, and distributes medicines, vaccines, parasiticides, dental, dermatology, and nutrition products for companion animals and livestock across 100+ countries, selling primarily through veterinary clinics, distributors, and online retailers.

What Virbac does

Virbac is a French animal health pharmaceutical company founded in 1968 and headquartered in Carros, France, listed on Euronext Paris (EPA:VIRP). It develops, manufactures, and distributes veterinary medicines, vaccines, parasiticides, dermatology products, dental products, diagnostics, nutritional supplements, and specialty therapeutics for companion animals (cats, dogs) and food-producing animals (cattle, swine, aquaculture). The company holds the #1 veterinarian-recommended dental brand (C.E.T.) and operates flagship parasiticide franchises including Sentinel and Iverhart, alongside newer specialty assets such as URSOLYX (feline muscle health) and Felanorm/Thyronorm (feline hyperthyroidism). Manufacturing is conducted at facilities in France, the United States, Argentina, Japan, India, and Chile, supported by wholly-owned distribution subsidiaries in 100+ countries.

The business operates on a B2B go-to-market model selling through veterinary clinics, animal health distributors, and online retailers, with end users including veterinarians, farmers, breeders, and pet owners. Revenue is split roughly 60% companion animals and 40% food-producing animals, with FY2025 revenue of €1.465 billion (7.9% organic growth) and Q1 2026 revenue of €384 million (+7.7%). The product mix is dominated by one-time pharmaceutical sales rather than recurring subscriptions. Growth has been substantially augmented by an active M&A program, including the €280 million Sasaeah acquisition (Japan, 2024), £100 million Felanorm/Thyronorm acquisition (2025), and earlier $410 million Sentinel brands acquisition from Eli Lilly (2015), alongside licensing deals such as the MabGenesis monoclonal antibody agreement (2025).

The company is led by CEO Paul Martingell and CFO Habib Ramdani, with governance undergoing a 2026 regional reorganization into three major regions. Virbac's strategic positioning emphasizes species-specific innovation, global distribution scale, and post-acquisition portfolio integration rather than technology-platform differentiation.

Virbac firmographics

Firmographics
Name
Virbac
Legal name
VIRBAC
Website
https://virbac.com
Company type
Public
Founded year
1968
Operating status
Operating
Headcount range
5,001–10,000 employees
Short description
Virbac is a French-listed veterinary pharmaceutical company that develops, manufactures, and distributes medicines, vaccines, parasiticides, dental, dermatology, and nutrition products for companion animals and livestock across 100+ countries, selling primarily through veterinary clinics, distributors, and online retailers.
Ownership category
akta.pro rank

Virbac industry classification

Industry
Product category
Veterinary Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Animal Food Manufacturing (31111)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAMAEAL
Veterinary Vaccines (Biologics)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAEAK
Biologics & Immunotherapies (Non-vaccine)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAEAD
Parasiticides & Ectoparasite Control (Flea/Tick/Heartworm)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYAFAEANAK
Veterinary Pharmacy, Vaccine & Biologics Services

Keywords

  • Veterinary pharmaceuticals
  • Animal health products
  • Veterinary vaccines
  • Companion animal medicine
  • Livestock pharmaceuticals

Where Virbac is headquartered

Location

Headquarters

HQ city
Carros
HQ country
France
HQ region
Europe

Offices3 records

Markets served

Virbac business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales

Revenue model

  1. Veterinary Pharmaceuticals and Medicines: Revenue generated from selling veterinary medicines, vaccines, parasiticides, antibiotics, and dermatology products to veterinarians and animal health distributors
  2. Companion Animal Products: Products for cats and dogs including nutritional supplements, dental care, dermatology, parasiticides, representing approximately 60% of total sales
  3. Food-Producing Animal Products: Products for cattle, swine, aquaculture including vaccines, antibiotics, and health management solutions

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Virbac product offering

Product offering

Core offering

Virbac develops, manufactures, and sells a comprehensive range of veterinary pharmaceuticals, vaccines, parasiticides, dermatology products, diagnostics, dental care solutions, and nutritional supplements for companion animals (cats and dogs) and food-producing animals (cattle, swine, aquaculture, poultry). The portfolio includes proprietary brands such as C.E.T.® dental products, Sentinel® and Iverhart® parasiticides, URSOLYX™ muscle health supplements, and Thyronorm/Felanorm for feline hyperthyroidism. Products are distributed globally in more than 100 countries through veterinary clinics, animal health distributors, and online retailers.

Product overview

Virbac is a global animal health company offering a comprehensive and practical range of veterinary products and services covering the majority of animal species and diseases. The company's portfolio includes companion animal health solutions (dermatology, parasiticides, vaccines, diagnostics, nutritional products including C.E.T.® dental products, and antibiotics), farm animal health products (cattle, aquaculture/salmon, swine), and specialty pharmaceuticals. Key products include C.E.T. AQUADENT® FR3SH® Dental Solution, URSOLYX™ Soft Chews for Cats, Sentinel® and Iverhart® parasiticide brands, and feline hyperthyroidism treatments (Thyronorm, Felanorm). The company has expanded through acquisitions including Globion (India poultry vaccines), Sasaeah (Japan farm animal vaccines), Centrovet (Chile aquaculture), and licensing agreements for therapeutic antibodies. Virbac serves veterinarians, farmers and pet owners in more than 100 countries.

Differentiator

Problem solved

Functional benefit

Brands

  • C.E.T. Veterinary dental brand, #1 veterinarian-recommended dental brand
  • URSOLYX
  • Felanorm
  • Thyronorm

Products and services

  • C.E.T. AQUADENT FR3SH Dental Solution Veterinary dental solution for dogs that controls plaque and tartar; carries the VOHC Seal of Acceptance and is sold through veterinary clinics and leading online retailers.
  • URSOLYX Soft Chews for Cats First muscle health supplement specifically formulated for cats to address muscle atrophy in aging, active or recuperating felines; key ingredient is ursolic acid; sold to veterinarians and through retail channels.
  • Felanorm Oral Solution Leading drug for feline hyperthyroidism acquired by Virbac from Norbrook; expands Virbac's portfolio of treatments for senior cats.
  • Thyronorm Liquid treatment for feline hyperthyroidism; distribution planned across UK, Australia, New Zealand and US markets; aids administration in cats.
  • Sentinel Flavor Tabs Major parasiticide for dogs acquired by Virbac from Novartis Animal Health; generates approximately $90-100 million in revenues in the United States.
  • Sentinel Spectrum Major parasiticide for dogs acquired by Virbac from Novartis Animal Health; generates approximately $90-100 million in revenues in the United States.
  • Iverhart Plus Internal parasiticide for dogs; part of Virbac's canine parasiticide portfolio in the United States.
  • Iverhart Max Internal parasiticide for dogs combining three active ingredients to provide wider protection including heartworm and tapeworm; marketed through veterinary channels in the United States.
  • Milpro Internal parasiticide for companion animals launched in France and Northern Europe as part of Virbac's parasiticide range.
  • Effitix Parasiticide product for companion animals launched in Europe; part of Virbac's external parasiticide portfolio.
  • Centrovet Aquaculture Products Aquaculture pharmaceutical products from Centrovet (Chile), a wholly-owned Virbac subsidiary, providing protection and treatment solutions for salmon and other aquaculture breeding operations.
  • Globion Poultry Vaccines Poultry vaccines from Globion India (now wholly-owned Virbac subsidiary), bolstering Virbac's position in the avian vaccines segment in India.
  • Sasaeah Animal Health Products Farm animal vaccines and pharmaceutical products from Sasaeah (Japan), a wholly-owned Virbac subsidiary with leadership in the Japanese cattle vaccine market and a broad pharmaceutical portfolio for major species.
  • C.E.T. Dental Products The number one veterinarian-recommended dental brand for pets, including dental solutions and hygiene products covering plaque and tartar control.
  • iVet Specialty Petfood Specialty petfood from iVet LLC (USA), a wholly-owned Virbac subsidiary bringing distribution, logistics and e-commerce expertise for petfood in the United States.

Quantifiable outcome

  • C.E.T. AQUADENT FR3SH Dental Solution received VOHC Seal of Acceptance for plaque and tartar control
  • +1 more outcomes

Companies that use Virbac

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles4 records

Virbac technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Virbac partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • PetlovecoreGTM or Marketing Partner · 18 June 2026Petlove, Brazil's largest pet ecosystem, partnered with Virbac as one of the major pharmaceutical firms for its PetVet medication benefits program offering up to 40% discounts on approximately 140 veterinary medications, targeting Brazil's 160 million pets
  • Ceva Animal HealthminorOthers · 10 April 2026Sébastien Huron, former CEO of Virbac (2017-2024), appointed as Deputy CEO of Ceva Animal Health as part of governance evolution
  • HABRI (Human Animal Bond Research Institute)coreStrategic or Co-development Partner · 17 February 2026Partnership to promote research and education on the human-animal bond and its health benefits, translating scientific research into practical insights for veterinary professionals and pet owners
  • MabGenesiscoreStrategic or Co-development Partner · 16 April 2025Licensing agreement for therapeutic antibodies for canine diseases, expanding pipeline in monoclonal antibody therapeutics
  • MACSOminorStrategic or Co-development Partner · 18 October 2024Agreement for swine health products, announced October 2024
  • PharmgateminorStrategic or Co-development Partner · 8 December 2021Collaboration with Pharmgate for FDA approval of tulathromycin injectable in the United States
  • Jectas InnovatorscoreStrategic or Co-development Partner · 29 September 2021Collaborative agreement for development of animal health vaccine(s), announced September 2021

Scale indicators8 records

Recent moves10 records

Expansion highlights6 records

Virbac competitors and assessment

Company assessment

Direct peers

  • Elanco Animal Health: Elanco is a global animal health company focused on companion animal and livestock pharmaceuticals, vaccines, and parasiticides. Its companion animal focus and product mix closely resemble Virbac's strategic priorities.
  • Norbrook Laboratories: Norbrook is a Northern Ireland-based veterinary pharmaceuticals company specializing in parasiticides, anti-infectives, and specialty therapeutics. Virbac acquired Thyronorm/Felanorm from Norbrook in 2025, evidencing direct portfolio overlap and competitive proximity.
  • Vetoquinol: Vetoquinol is a French-headquartered global animal health company specializing in veterinary pharmaceuticals and supplements for companion and production animals. Its portfolio and geographic mix closely parallel Virbac's, making it a strong mid-cap peer.
  • MSD Animal Health (Merck Animal Health): MSD Animal Health is a leading global animal health division offering pharmaceuticals, vaccines, and parasiticides; it acquired Sentinel US rights from Virbac in 2020 and competes across Virbac's full portfolio breadth.
  • Phibro Animal Health: Phibro is a global animal health and nutrition company offering vaccines, parasiticides, and nutritional specialties for livestock and poultry, with strong overlap to Virbac's food-producing animal segment.
  • Dechra Pharmaceuticals: Dechra is a UK-based specialty veterinary pharmaceuticals company focused on companion animal endocrinology, dermatology, and critical care, overlapping with Virbac's specialty therapeutics and parasiticide franchises.
  • Zoetis: Zoetis is the world's largest pure-play animal health company, offering pharmaceuticals, vaccines, diagnostics, and parasiticides across companion and livestock animals. It is the closest direct competitor to Virbac across virtually every product category and geography.
  • Ceva Animal Health: Ceva is a France-based global animal health company providing vaccines, pharmaceuticals, and companion animal products. As a fellow French-headquartered peer of similar size and scope, it is a closely comparable direct competitor, especially in Europe and emerging markets.
  • Boehringer Ingelheim Animal Health: Boehringer's animal health division offers a broad portfolio of veterinary vaccines, parasiticides, and therapeutics for companion and food-producing animals, directly overlapping with Virbac's core franchises. It is one of the top global animal health players.

Broad incumbents

  • IDEXX Laboratories: IDEXX is a leading veterinary diagnostics company offering in-clinic lab equipment and tests; while diagnostics is only a portion of Virbac's portfolio, IDEXX is a benchmark for veterinary channel economics and product premium pricing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Virbac social profiles

Digital presence

Virbac compliance and trust

Trust signal

Compliance1 record

Virbac financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Virbac leadership team

Management profile

Number of profiles

Profiles6 records

Virbac subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

Virbac funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Virbac M&A and investment

M&A and investment

M&A8 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Virbac

What does Virbac do?

Virbac develops, manufactures, and sells a comprehensive range of veterinary pharmaceuticals, vaccines, parasiticides, dermatology products, diagnostics, dental care solutions, and nutritional supplements for companion animals (cats and dogs) and food-producing animals (cattle, swine, aquaculture, poultry). The portfolio includes proprietary brands such as C.E.T.® dental products, Sentinel® and Iverhart® parasiticides, URSOLYX™ muscle health supplements, and Thyronorm/Felanorm for feline hyperthyroidism. Products are distributed globally in more than 100 countries through veterinary clinics, animal health distributors, and online retailers.

Is Virbac a public or private company?

Virbac is a public company. It is classified as public and is currently operating.

When was Virbac founded?

Virbac was founded in 1968. It employs 5,001 to 10,000 people.

Where is Virbac based?

Virbac is headquartered in Carros, France, in the Europe region.

How does Virbac make money?

Three revenue lines are on record. Veterinary Pharmaceuticals and Medicines are the primary driver. The others are companion Animal Products and food-Producing Animal Products.

Who are Virbac's main competitors?

Direct peers on record are Elanco Animal Health, Norbrook Laboratories, Vetoquinol, MSD Animal Health (Merck Animal Health), Phibro Animal Health, Dechra Pharmaceuticals, Zoetis, Ceva Animal Health and Boehringer Ingelheim Animal Health. IDEXX Laboratories is listed as a broad incumbent.

Does Virbac have an API?

No public API is recorded for Virbac.

What industry is Virbac in?

Virbac's product category is Veterinary Pharmaceuticals. Its primary akta.pro industry code is HLAMAEAL, Veterinary Vaccines (Biologics), with a secondary code of HLAMAEAK, Biologics & Immunotherapies (Non-vaccine). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comVirbac at Jefferies Global Healthcare Conference: growth push sharpensVirbac outlined its growth strategy at the Jefferies Global Healthcare Conference, targeting 7.5% organic revenue growth for 2026 and a 20% EBITDA margin by 2030. The company plans record capital spending of EUR 125 million and highlighted its seven Supercharge platforms as key growth drivers.InvestegateVirbac to Participate in the Jefferies Global Healthcare Conference in LondonVirbac announced that CEO Paul Martingell and Group CFO Habib Ramdani will present and answer questions at the Jefferies Global Healthcare Conference in London on November 18, 2026, at 16:30 GMT. A live webcast and replay will be available on Virbac's investor site.GlobeNewswireVirbac to Participate in the Jefferies Global Healthcare Conference in LondonVirbac announced that CEO Paul Martingell and CFO Habib Ramdani will present at the Jefferies Global Healthcare Conference in London on November 18, 2026. The live webcast is available on the company's investor page, with a replay following the event.TradingViewVIRP: 2026 growth guidance and a 2030 strategy centered on innovation, execution and productivityVirbac SA issued 2026 growth guidance of 5.5%–7.5% revenue growth at constant rates and scope, targeting the upper end with a 17% EBIT(A) margin. The company's 2030 strategy prioritizes innovation, digital execution, and productivity to sustain above-market growth and margin expansion.HrtodayElijah Reid Appointed Vice President, Human Resources, North America at VirbacElijah Reid joined Virbac as Vice President, Human Resources, North America, leading the region's HR function and people strategy. He previously held senior HR roles at Cencora and Galderma. In the new role, he will focus on organizational capabilities, talent development, and employee engagement.PR NewswireVirbac Corporation appoints Jason Bailey as CFO and Elijah Reid as VP of HR in a continuous effort to transform the organization and accelerate strategic growthVirbac Corporation appointed Jason Bailey as CFO and Elijah Reid as VP of HR, effective November 2, 2026. Bailey will lead regional financial strategy and operational alignment, while Reid will oversee workforce strategy and HR transformation. The appointments aim to align financial discipline and human capital to drive sustainable growth across North American markets.InvestegateVirbac : Declaration of the number of shares and voting rights 10/2026Virbac declared its share capital and voting rights for October 30, 2026, listing 8,390,660 shares representing the share capital. The gross total of voting rights is 12,704,102, with a net total of 12,695,066 after excluding shares without voting rights.The future of tradingVirbac : Declaration of the number of shares and voting rights 10/2026Virbac declared its total number of shares and voting rights for October 30, 2026, on Euronext Paris. The company reported 8,390,660 shares representing the share capital, with gross voting rights of 12,704,102 and net voting rights of 12,695,066.The future of tradingVirbac Reports 8,390,660 Issued Shares as of Oct. 30Virbac disclosed 8,390,660 issued shares as of Oct. 30, 2026, with gross voting rights totaling 12,704,102 and net voting rights at 12,695,066. The disclosure was published via GlobeNewswire on Nov. 4, 2026.